Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: N Engl J Med. 2013 Jun 2;369(2):122–133. doi: 10.1056/NEJMoa1302369

Figure 2. Tumor regressions of patients who received concurrent nivolumab and ipilimumab.

Figure 2

In Panel A, regression of tumors in a 52-year old patient who received 1 mg/kg nivolumab + 3 mg/kg ipilimumab, the maximum tolerated dose. This patient presented with extensive neck, mediastinal, axillary, abdominal and pelvic lymphadenopathy, bilateral pulmonary nodules, small bowel metastasis, peritoneal implants and diffuse subcutaneous nodules. Baseline lactate dehydrogenase (LDH) was 2.25 × upper limit of normal, hemoglobin was 9.7 g/dL, and symptoms included nausea and vomiting. Within 4 weeks of treatment the LDH normalized, symptoms improved (appetite increased, nausea decreased), and cutaneous lesions were regressing. At week-12 scans, there was marked reduction in all areas of disease. Arrows denote location of metastatic disease. In Panel B, regression of tumors in a 61-year-old patient who received 0.3 mg/kg nivolumab + 3 mg/kg ipilimumab. The patient presented with stage IV (M1c) melanoma of an unknown primary site, metastatic to the stomach and the mesentery. LDH was 225 and hemoglobin was 9.6 g/dL after a recent transfusion. Twelve weeks after the initiation of study treatment, a CT scan showed an 86% reduction in the bulky disease burden.